Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ulrika Wählby Hamren (Mölndal, Sweden), Ulrika Wählby Hamrén, Fredrik Öhrn, Ajay Aggarwal. Dose-FEV1 modeling to support future development of AZD2115, a dual acting bronchodilator for the treatment of COPD. Eur Respir J 2015; 46: Suppl. 59, 2128

Member's Comments

No comment yet.

Related content which might interest you: Validation of a new inhaled therapeutic algorithm for the stable COPD patient: The COPD easy treatment project Source: International Congress 2015 – Management of COPD and other respiratory diseases in primary care Year: 2015 Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Comparison of protective effect of bronchodilators in COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 The influence of type of inhalation device on adherence of COPD patients to inhaled medication Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The patient’s role in the choice of new inhaler devices and dosing regimens for asthma and COPD: A preference study Source: International Congress 2016 – Kaleidoscope of respiratory nursing Year: 2016 LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Distribution and outcomes of the new Spanish phenotype-based guideline for COPD Source: International Congress 2014 – COPD exacerbations Year: 2014 Effects of pharmacist interventions to inhalation medication adherence and lung functions in COPD patients at one stop service clinic Source: International Congress 2014 – COPD exacerbations Year: 2014 What is the best biomarker of COPD stability? Source: International Congress 2015 – COPD: chronic disease and comorbidities Year: 2015 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Combination therapy versus separate therapy in real-life primary care asthma patients Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Differences in adherence to common inhaled medications in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Effect of breathing parameters on lung dose in case of two combination drugs used in asthma and COPD therapy Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 A new clinically relevant method of calculating adherence Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Optimal adherence with inhaled corticosteroids is related to better health status Source: International Congress 2015 – Novel strategies for the management of asthma, COPD and airway infections Year: 2015 The effectiveness of anti-inflammatory therapy for chronic obstructive pulmonary disease complicated by ischemic heart disease (new medication - new opportunities) Source: International Congress 2014 – Comorbidities Year: 2014 Clinically important deteriorations in COPD as a measure of response to dual and mono bronchodilator therapy with and without inhaled corticosteroids Source: International Congress 2015 – New data on established treatments for COPD Year: 2015